TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

LUYE PHARMA

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: US

Quick snapshot

LUYE PHARMA

ST13

US500000079080769

Class

5

Filing

79080769

Registration

4130180

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

59

Latest update

09/03/2023

Classification

Registered

Trademark type

Combined

Nice classes

5

Filing date

11/10/2009

Registration date

04/24/2012

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

11/11/2022

Last transaction

12/21/2022

Responsible office

United States Patent and Trademark Office

Status code

709

Official register

Principal Register

Drawing code

3

Owner type

03

Owner location

CN

Examiner

DAWE III, WILLIAM H

Law office

L80

Current location

GENERIC WEB UPDATE

Mark description

The mark consists of a miscellaneous design on the left, four Chinese characters on the right and the words "LUYE PHARMA" on the top of the Chinese characters.

Holders and representatives

Holders

Shandong Luye Pharmaceutical Co., Ltd.

Representatives

MATTHEW D. ASBELL LADAS & PARRY LLP

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Medicines for human purposes and drugs for medical purposes namely, sodium aescinate injections for the treatment of cerebral edema and edema caused by trauma or operations and of venous back flow obstruction diseases, sodium glycididazole injections in the nature of radiosensitizer for the radiotherapy of solid tumors such as head and neck tumor, lung cancer, and esophageal cancer, and reduced glutathione injections for the treatment of alcoholic fatty liver, alcoholic liver fibrosis, alcoholic liver cirrhosis, acute alcoholic hepatitis, poisoning by radiotherapy, drugs and chemicals; medicinal drinks; pharmaceutical preparations, chemico-pharmaceutical preparations, and chemical preparations for pharmaceutical purposes, namely, sodium aescinate tablets for the treatment of venous edema and soft tissue swelling due to various causes, smectite dispersible tablets and smectite powder sachets for the treatment of acute and chronic bacillary diarrhea of adults and children and for the treatment of pains caused by gullet, stomach and duodenum diseases but not used for spasmolysant, and elcatonin injections for the treatment of bone pains caused by osteoporesis, of hypercalaemia, and of scleromalacia; biological preparations for medical purposes; tonics being medicines, namely, largetrifoliolious bugbane rhizome tablets for the treatment of the pre-menopausal, menopausal and post menopausal syndrome of women, used to relieve the symptoms of hot sweating, restlessness, insomnia, flank pain, dizziness, and tinnitus; gelatin for medical purposes, namely, compound sodium aescinate gel used to relieve the swelling caused by inflammation, degenerative diseases, wounds, ridge pains such as spondylalgia, lumbago, rachialgia, sciatica, closed type acute tissue injuries, lesion in the inter-vertebral disks, varicose of veins, and peritonitis and phlebitis, capsaicin gel used to relieve arthritis and/or muscle pains caused by osteoarthritis, rheumatoid arthritis, myelitis, and fibromyalgia pains caused by sprains to joints; capsules for pharmaceutical purposes, namely, pantoprazole pellets capsules for the treatment of duodenal ulcer, gastric ulcer and acute pathological changes of gastric mucosa, reflux esophagitis and Zollinger-Ellison Syndrome

Publications

History of USPTO decisions and trademark events.

59 publications found

INNT

TOTAL INVALIDATION PROCESSED BY THE IB

09/03/2023

XXSS

GENERIC MADRID TRANSACTION SENT TO IB

07/27/2023

XXCR

GENERIC MADRID TRANSACTION CREATED

07/27/2023

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

07/11/2023

C71T

CANCELLED SECTION 71

11/11/2022

REM4

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED

04/24/2021

RNWL

INTERNATIONAL REGISTRATION RENEWED

11/28/2019

NA71

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED

08/12/2019

71AG

REGISTERED-SEC.71 ACCEPTED

08/12/2019

NREP

NEW REPRESENTATIVE AT IB RECEIVED

06/21/2019

EROP

TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED

03/14/2019

PR71

POST REGISTRATION ACTION MAILED - SEC.71

01/18/2019

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

11/15/2018

ES71

TEAS SECTION 71 RECEIVED

10/18/2018

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

12/15/2016

GPNX

NOTIFICATION PROCESSED BY IB

11/14/2012

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

08/29/2012

FICS

FINAL DISPOSITION NOTICE SENT TO IB

08/03/2012

FIMP

FINAL DISPOSITION PROCESSED

08/02/2012

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

07/24/2012

R.PR

REGISTERED-PRINCIPAL REGISTER

04/24/2012

GPNX

NOTIFICATION PROCESSED BY IB

02/11/2012

PUBO

PUBLISHED FOR OPPOSITION

02/07/2012

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

01/18/2012

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

01/18/2012

NPUB

NOTICE OF PUBLICATION

01/18/2012

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

01/04/2012

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

01/03/2012

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

12/29/2011

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

12/29/2011

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

12/29/2011

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

09/21/2011

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

09/21/2011

CNRT

NON-FINAL ACTION MAILED

08/09/2011

CNRT

NON-FINAL ACTION WRITTEN

08/08/2011

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

07/19/2011

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

07/19/2011

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

07/19/2011

CNRT

NON-FINAL ACTION MAILED

04/26/2011

CNRT

NON-FINAL ACTION WRITTEN

04/26/2011

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

03/31/2011

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

03/31/2011

ALIE

ASSIGNED TO LIE

03/07/2011

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

02/23/2011

CNRT

NON-FINAL ACTION MAILED

10/07/2010

CNRT

NON-FINAL ACTION WRITTEN

10/07/2010

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/17/2010

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/17/2010

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/17/2010

RFNT

REFUSAL PROCESSED BY IB

06/04/2010

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

04/27/2010

RFRR

REFUSAL PROCESSED BY MPU

04/27/2010

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

04/27/2010

CNRT

NON-FINAL ACTION WRITTEN

04/26/2010

MAFR

APPLICATION FILING RECEIPT MAILED

04/23/2010

DOCK

ASSIGNED TO EXAMINER

04/19/2010

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

04/19/2010

LIMS

LIMITATION OF GOODS/SERVICES FROM IB ENTERED

04/16/2010

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

04/15/2010

Continuous trademark protection

Get notified about every new filing that threatens LUYE PHARMA or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.